First Time Loading...

Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 3.56 USD 1.14% Market Closed
Updated: May 28, 2024

Fate Therapeutics Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fate Therapeutics Inc
Capital Expenditures Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Fate Therapeutics Inc
NASDAQ:FATE
Capital Expenditures
-$3m
CAGR 3-Years
27%
CAGR 5-Years
5%
CAGR 10-Years
-17%
Abbvie Inc
NYSE:ABBV
Capital Expenditures
-$795m
CAGR 3-Years
3%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Gilead Sciences Inc
NASDAQ:GILD
Capital Expenditures
-$581m
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Capital Expenditures
-$998m
CAGR 3-Years
-16%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Capital Expenditures
-$464.7m
CAGR 3-Years
-14%
CAGR 5-Years
-41%
CAGR 10-Years
-25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Capital Expenditures
-$809.1m
CAGR 3-Years
-13%
CAGR 5-Years
-16%
CAGR 10-Years
-15%

See Also

What is Fate Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-3m USD

Based on the financial report for Mar 31, 2024, Fate Therapeutics Inc's Capital Expenditures amounts to -3m USD.

What is Fate Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-17%

Over the last year, the Capital Expenditures growth was 89%. The average annual Capital Expenditures growth rates for Fate Therapeutics Inc have been 27% over the past three years , 5% over the past five years , and -17% over the past ten years .